Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07064759 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Study acronym: 4FRONT-2
StatusRecruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 43 → 94 locationsv4
  2. Enrollment target: 400 to 480 Study sites: 24 to 43v3 Show 1 more changeShow less
    • Study sites: 24 to 43
  3. Primary endpoint revised Study sites: 3 to 24 · Start date changed from estimate of Jul 2025 to Jul 22, 2025 · Secondary endpoints revised (5) · 1 morev2 Show 4 more changesShow less
    • Study sites: 3 to 24
    • Start date changed from estimate of Jul 2025 to Jul 22, 2025
    • Secondary endpoints revised (5)
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
A Phase 3, Randomized, Double-Masked, Active-Controlled Trial in Adults with Macular Neovascularization Secondary to Age-Related Macular Degeneration
Trial Details
NCT Number NCT07064759
Lead Sponsor 4D Molecular Therapeutics
Conditions Neovascular Age-Related Macular Degeneration (nAMD)
Enrollment 480 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov